Swedish Orphan Biovitrum S.R.O. (Czech Republic)

Swedish Orphan Biovitrum s.r.o. represents Sobi in the Czech Republic as part of an international biopharmaceutical company focused on improving the lives of patients with rare diseases through access to innovative treatments. The business is organized around therapeutic areas in hematology, immunology and specialized care, with a stated leading position in hemophilia treatment and an emphasis on advancing treatment standards and supporting the care ecosystem for hemophilia patients, alongside expansion into additional hematologic indications. In immunology, the portfolio focus is positioned on innovative medicines built on long-standing experience in rare diseases, with continued search for new opportunities to expand patient access to innovation. Geographic scope combines local Czech-market engagement with the broader international footprint of Sobi across multiple countries. Strategically, the company positions around rare-disease specialization, innovation access and therapeutic depth in hematology and immunology, supported by sustainability and transparency themes in corporate positioning.